HOME >> BIOLOGY >> NEWS
Pittsburgh researchers engineer and successfully test SARS corona vaccine in animal model

PITTSBURGH, Dec. 4 -- Research by scientists at the University of Pittsburgh School of Medicine and the Graduate School of Public Health (GSPH) in collaboration with colleagues at the Centers for Disease Control and Prevention (CDC) in Atlanta has shown that an adenoviral-based vaccine can induce SARS-coronavirus (SARS-CoV)-specific T-cell and virus-neutralizing antibody responses.

The study, which represents the first published work on the development of a SARS vaccine and comes only a few months after the SARS coronavirus was identified and its genome was sequenced, is reported in a fast track research letter in the Dec. 6 issue of The Lancet.

"It is our hope that this research will lead to a protective vaccine against SARS," stated project leader Andrea Gambotto, M.D., from the departments of surgery and medicine, division of infectious diseases and the Molecular Medicine Institute (MMI) at the University of Pittsburgh School of Medicine.

In the study, researchers immunized six rhesus macaques intramuscularly with a combination of three SARS-CoV vectors. Two additional macaques were immunized with the same amount of empty adenoviral vector and served as controls. After 28 days, the animals received a second vaccination. Six weeks after vaccination, T-cells and antibodies against SARS were detected in all six of the immunized animals, but not in either of the control animals. The intensity of the response varied among animals but was generally largest after the booster vaccination, according to the Pittsburgh researchers. Serum samples from the vaccinated animals, but not from the controls, showed strong neutralizing capacity against SARS-CoV.

"From a scientific perspective, several points are important. We obtained the recombinant vaccine by engineering a common cold virus to express the SARS coronavirus antigens. This is a successful strategy that we are exploring for other infectious diseases such as HIV," said Dr. Gambott
'"/>

Contact: Frank Raczkiewicz
RaczkiewiczFA@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
4-Dec-2003


Page: 1 2 3

Related biology news :

1. University of Pittsburgh receives $10 million grant for head and neck cancer
2. University of Pittsburgh medical center among first to implant heart assist device
3. University of Pittsburgh receives NIH funding to develop heart assist device for infants
4. Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon
5. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
6. Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers
7. University of Pittsburgh scientist honored for major accomplishment in cancer research
8. Worlds largest scientific society to hold regional meeting in Pittsburgh
9. University of Pittsburgh named cooperative research center for muscular dystrophy
10. Infectious disease study findings presented by University of Pittsburgh scientists
11. University of Pittsburgh study links gynecological complaint to increased risk for herpes

Post Your Comments:
(Date:2/10/2015)... Mass., Feb. 10, 2015  Alere Inc. (NYSE: ... its financial results for the quarter ended December ... Officer and President of Alere said, "We made ... Alere as the global leader in rapid diagnostics ... the Alere Health divestiture in early January enabled ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
(Date:3/5/2015)... March 05, 2015 RMI ... and chronic orthopedic conditions such as meniscal tears, ... elbow, and joint pain due to degenerative conditions ... during orthopedic surgeries to promote better post-surgical outcomes. ... in nearly pain-free bone marrow harvesting with two ...
(Date:3/4/2015)... March 04, 2015 USDM Life ... the life sciences industry, hired David Blewitt ... Cloud Compliance Services and Solutions at USDM Life ... based applications while maintaining compliance with government regulations worldwide. ... been an accomplished life sciences regulatory and IS compliance ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Launched by the Assistance ... in December 2011, ,SARAH, - the French national ... sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled more ... SARAH, a large French study of patients with ... has completed patient enrolment, exceeding its 400-patient target, according ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
Cached News: